Lantheus Holdings Inc. (LNTH) Downgraded by Zacks Investment Research to Hold
According to Zacks, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States. “
Other equities research analysts have also recently issued reports about the stock. Credit Suisse Group AG set a $4.00 price target on shares of Lantheus Holdings and gave the company a hold rating in a research report on Friday, August 5th. Jefferies Group reiterated a buy rating on shares of Lantheus Holdings in a research report on Friday, August 5th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Lantheus Holdings has a consensus rating of Hold and an average target price of $7.40.
Shares of Lantheus Holdings (NASDAQ:LNTH) opened at 8.23 on Wednesday. The stock has a 50 day moving average of $8.40 and a 200 day moving average of $4.40. The stock has a market cap of $250.08 million, a PE ratio of 9.29 and a beta of 0.45. Lantheus Holdings has a 12 month low of $1.76 and a 12 month high of $10.10.
Lantheus Holdings (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, August 4th. The company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.18. Lantheus Holdings had a net margin of 9.00% and a negative return on equity of 11.75%. The business earned $78 million during the quarter, compared to analysts’ expectations of $72.66 million. On average, equities analysts anticipate that Lantheus Holdings will post $0.55 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. increased its position in shares of Lantheus Holdings by 6,447.0% in the second quarter. BlackRock Inc. now owns 28,021 shares of the company’s stock worth $103,000 after buying an additional 27,593 shares in the last quarter. Acrospire Investment Management LLC purchased a new position in shares of Lantheus Holdings during the second quarter worth about $107,000. TFS Capital LLC purchased a new position in shares of Lantheus Holdings during the second quarter worth about $156,000. Oxford Asset Management purchased a new position in shares of Lantheus Holdings during the second quarter worth about $158,000. Finally, Paloma Partners Management Co purchased a new position in shares of Lantheus Holdings during the second quarter worth about $179,000. Institutional investors own 30.15% of the company’s stock.
Lantheus Holdings Company Profile
Lantheus Holdings, Inc develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities.
Receive News & Stock Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related stocks with our FREE daily email newsletter.